ARID1A is an inclusion eligibility criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].